Prognostic significance of p53 mutation in suboptimally resected advanced ovarian carcinoma treated with the combination chemotherapy of paclitaxel and carboplatin.
The prognostic significance of p53 mutation, microsattelite instability and DNA mismatch protein hMLH1 expression in suboptimally resected advanced ovarian carcinoma treated with the combination chemotherapy of paclitaxel and carboplatin was evaluated. The overall combination chemotherapy response rate and the complete remission rate were significantly higher among patients with mutant p53 tumors than those with wild-type p53 tumors (35/42 (83%) vs. 32/58 (55%); P=0.003 and 18/42 (43%) vs. 16/58 (28%); P=0.03, respectively). This tendency apparently existed in non-serous carcinoma, but not in serous carcinoma. Univariate analysis showed that the risk of death due to disease and risk of progression was significantly lower among patients with p53 mutation (P=0.0357 and 0.0281, respectively). However, the presence of microsattelite instability or loss of hMLH1 expression was not associated with either the clinical response or prognosis. Determining p53 mutational status can be useful in predicting therapeutic response to drugs in ovarian carcinoma, especially in non-serous tumors.
Ueno
Yuko
Y
Department of Obstetrics and Gynecology, Osaka University Faculty of Medicine, 2-2 Yamadaoka, Suita 565-0871, Osaka, Japan.
Enomoto
Takayuki
T
Otsuki
Yoshiro
Y
Sugita
Nagatoshi
N
Nakashima
Ryuichi
R
Yoshino
Kiyoshi
K
Kuragaki
Chie
C
Ueda
Yutaka
Y
Aki
Tadaatsu
T
Ikegami
Hiromasa
H
Yamazaki
Masato
M
Ito
Kimihiko
K
Nagamatsu
Masaaki
M
Nishizaki
Takamichi
T
Asada
Masahiro
M
Kameda
Takashi
T
Wakimoto
Akinori
A
Mizutani
Takahiro
T
Yamada
Takako
T
Murata
Yuji
Y
D018262:Adenocarcinoma, Clear Cell / Q000188:drug therapy / Q000235:genetics / Q000601:surgery; D002288:Adenocarcinoma, Mucinous / Q000188:drug therapy / Q000235:genetics / Q000601:surgery; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D016190:Carboplatin / Q000008:administration & dosage; D018269:Carcinoma, Endometrioid / Q000188:drug therapy / Q000235:genetics / Q000601:surgery; D018284:Cystadenocarcinoma, Serous / Q000188:drug therapy / Q000235:genetics / Q000601:surgery; D005260:Female; D016158:Genes, p53 / Q000235:genetics*; D006801:Humans; D018895:Microsatellite Repeats / Q000187:drug effects / Q000235:genetics; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000235:genetics* / Q000601:surgery; D017239:Paclitaxel / Q000008:administration & dosage; D011379:Prognosis; D011446:Prospective Studies; D015996:Survival Rate
D016190:Carboplatin; D017239:Paclitaxel